Clavis Pharma Elects Robert J. Spiegel to its Board of Directors
News May 30, 2011
Clavis Pharma ASA, has announced that Robert J. Spiegel, MD, has been elected to its Board of Directors at the Company’s annual general meeting held in Oslo on May 26, 2011.
Dr. Spiegel has gained extensive clinical and corporate development experience in the biotechnology and pharmaceutical industry in a career spanning over 30 years.
He spent over 25 years at Schering-Plough where he joined as the first Director for Oncology Clinical Research, and then subsequently held several senior executive positions, such as Senior Vice President for the company’s Clinical Research department and Chief Medical Officer.
During his time at Schering-Plough he took numerous drug candidates through clinical development to FDA and EMA approval, and has also chaired the company’s Oncology Development Team for more than ten years.
In addition Dr. Spiegel has held several research positions at the Department of Medicine at New York University, and was a Research Associate at the National Cancer Institute, where he received his Oncology fellowship.
Dr. Spiegel founded and is the principal of Spiegel Consulting LLC and an Associate Fellow at the University of Pennsylvania’s Center for Bioethics. He is also an Advisor to private equity firm Warburg Pincus and serves on the Boards of Geron Corporation, Capstone Therapeutics and Talon Therapeutics.
Dr. Robert J. Spiegel, commented: “I am very pleased to be joining Clavis Pharma at this exciting time in its development, with two novel cancer drug candidates in pivotal clinical trials. I am looking forward to working with the Company’s Board and management team, and believe that the experience I have gained in bringing a large number of drug candidates through to approval internationally will allow me to make a very positive contribution to the future development of the company.”
Anders P. Wiklund, Chairman of Clavis Pharma, commented: “I am delighted to welcome Bob to the Board with his vast experience in the field of oncology and interaction with regulatory authorities worldwide. He will prove to be a tremendous asset as the Company advances its strategy to become a successful international cancer-focused drug company.”
Following today’s announcement, the board of Clavis Pharma comprises Anders P. Wiklund (Chairman), Geir Stormorken (Deputy Chairman), Annette Clancy, Kaci Kullman Five, Karol Sikora and Hilde H. Steineger and Robert J. Spiegel.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE